Loading
Lung Cancer Treatments and Mutations / Chemokine Receptors and Signaling · Journal article
Frontiers in Immunology · September 7, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review proposing circulating cytokines (TNF-α, IFN-γ, IL-6, IL-8, IL-17A, IL-1β, IL-2, IL-5, IL-10) as potential dynamic biomarkers for PD-1 inhibitor response and prognosis in NSCLC. The authors summarize mechanistic plausibility and emerging clinical associations but acknowledge inconsistency in findings across studies and do not present a validated predictive model or prospective evidence.
Narrative review. Patients with advanced non-small cell lung cancer (NSCLC) receiving PD-1 inhibitor therapy.
Nine circulating cytokines (TNF-α, IFN-γ, IL-6, IL-8, IL-17A, IL-1β, IL-2, IL-5, IL-10) show associations with response, survival, and immune-related adverse events during PD-1 blockade. Declines in IL-6, IL-8, IL-17A, and IL-10 together with transient increases in IFN-γ and TNF-α may indicate favorable immune reinvigoration, but findings remain inconsistent across studies. Circulating cytokines offer a minimally invasive alternative to tissue-based biomarkers constrained by tissue accessibility and intratumoral heterogeneity.
Nine circulating cytokines (TNF-α, IFN-γ, IL-6, IL-8, IL-17A, IL-1β, IL-2, IL-5, IL-10) show associations with response, survival, and immune-related adverse events during PD-1 blockade.
Circulating cytokines are proposed as a potentially useful dynamic monitoring tool for PD-1 blockade response, but the current evidence is too inconsistent and preliminary to guide clinical decision-making. Clinicians should regard this as a hypothesis-generating framework requiring prospective validation before adoption.
A narrative review synthesizing mechanistic concepts and scattered evidence about circulating cytokines as potential biomarkers, but acknowledging inconsistency across studies and lack of validated clinical utility.
As stated by the source record.
Circulating cytokines are proposed as a potentially useful dynamic monitoring tool for PD-1 blockade response, but the current evidence is too inconsistent and preliminary to guide clinical decision-making. Clinicians should regard this as a hypothesis-generating framework requiring prospective validation before adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Programmed death 1 (PD-1) inhibitors have transformed the treatment of advanced non-small cell lung cancer (NSCLC), but durable responses remain limited to a subset of patients. Conventional biomarkers, including PD-L1 expression and tumor mutational burden, are constrained by tissue accessibility, intratumoral heterogeneity, and limited capacity for dynamic monitoring. Circulating cytokines offer a minimally invasive alternative because they reflect systemic inflammation, antitumor immunity, and treatment-related immune activation. Evidence indicates that serum levels and on-treatment changes in TNF-α, IFN-γ, IL-6, IL-8, IL-17A, IL-1β, IL-2, IL-5, and IL-10 are associated with response, survival, and immune-related adverse events during PD-1 blockade. In general, declines in IL-6, IL-8, IL-17A, and IL-10, together with transient increases in IFN-γ and TNF-α, may indicate favorable immune reinvigoration, although findings remain inconsistent across studies. This review summarizes the biological functions, mechanistic roles, and clinical relevance of circulating cytokines as dynamic biomarkers, evaluates their potential values and current limitations in predicting the efficacy of PD-1 inhibitor therapy in NSCLC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.